Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 2439Neoplasms 1845Carcinoma, Non-Small-Cell Lung 1615Prostatic Neoplasms 1315Colorectal Neoplasms 1149Lung Neoplasms 993Neoplasm Metastasis 838Multiple Myeloma 802Leukemia, Myeloid, Acute 778Ovarian Neoplasms 686Pancreatic Neoplasms 673Melanoma 669Squamous Cell Carcinoma of Head and Neck 592Carcinoma, Hepatocellular 571Recurrence 570Brain Neoplasms 531Glioblastoma 521Stomach Neoplasms 506Head and Neck Neoplasms 504Triple Negative Breast Neoplasms 474Lymphoma 463Uterine Cervical Neoplasms 457Carcinoma, Renal Cell 430Precursor Cell Lymphoblastic Leukemia-Lymphoma 421Lymphoma, Non-Hodgkin 392Endometrial Neoplasms 386Sarcoma 372Lymphoma, Follicular 358Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 356

Interventions

Paracentesis 2irinotecan sucrosofate 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Malignant Ascites × 1 year × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

NCT07490626 2026-03-27

Paracentesis

University of Utah

Phase NA Not yet recruiting
20 enrolled

Malignant Ascites

NCT07397819 2026-02-09

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

Sun Yat-sen University

Phase 1/2 Recruiting
48 enrolled

Malignant Ascites

NCT06266091 2025-07-20

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 2 Completed
115 enrolled

Malignant Ascites

NCT07007988 2025-06-06

SIM0388-101

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Recruiting
50 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡